Table 1 Baseline demographics and characteristics of 135 breast cancer patients included in the TailorDose I study.
500 mg cyclophosphamide | 600 mg cyclophosphamide | |
|---|---|---|
N | N | |
Number of patients—no. (%) | 67 (100.0) | 68 (100.0) |
Hospital site—no. (%) | ||
Radiumhemmet, Karolinska University Hospital | 53 (79.1) | 56 (82.4) |
Oncology clinic, Danderyd | 14 (20.9) | 12 (17.6) |
Age at diagnosis | ||
Median (interquartile range), yr | 53 (47–61) | 61 (49–68) |
Categories—no. (%) | ||
< 51 | 29 (43.3) | 19 (28.0) |
51–60 | 20 (29.8) | 14 (20.6) |
> 60 | 18 (26.9) | 35 (51.4) |
Weigh—kg, mean (standard deviation) | 70.5 (13.3) | 71.4 (12.9) |
Length—cm, mean (standard deviation) | 165.5 (5.0) | 166.4 (6.3) |
Body Mass Index—h2/w, mean (standard deviation) | 25.7 (4.7) | 25.8 (4.5) |
Body surface area—m2, mean (standard deviation) | 1.8 (0.2) | 1.8 (0.2) |
Primary tumour site—no. (%) | ||
Left | 38 (57.6) | 41 (60.3) |
Right | 28 (42.4) | 27 (39.7) |
Histology grade—no. (%) | ||
I | 4 (6.0) | 5 (7.4) |
II | 21 (29.9) | 30 (44.1) |
III | 41 (59.6) | 33 (48.5) |
Not done | 1 (1.5) | 0 (0.0) |
Estrogen receptor—no. (%) | ||
Positive | 52 (77.6) | 53 (77.9) |
Negative | 15 (22.4) | 15 (22.1) |
Progesteron receptor—no. (%) | ||
Positive | 44 (65.7) | 50 (73.5) |
Negative | 23 (34.3) | 18 (26.5) |
HER2Neu Status—no. (%) | ||
0 | 23 (34.3) | 34 (50.0) |
1+ | 15 (22.4) | 14 (20.6) |
2+ | 11 (16.4) | 10 (14.7) |
3+ | 16 (23.9) | 9 (13.2) |
Not done | 2 (3.0) | 1 (1.5) |
HER2Neu Fish—no. (%) | ||
Yes | 20 (29.9) | 12 (17.7) |
No | 11 (16.4) | 10 (14.7) |
Not done | 36 (53.7) | 46 (67.6) |
Smoking status during treatment—no. (%) | ||
Smoker | 11 (16.4) | 7 (10.3) |
Non-smoker | 54 (80.6) | 56 (2.4) |
Unknown | 2 (3.0) | 5 (7.3) |
